HAE:NYE-Haemonetics Corporation (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 93.38

Change

+1.98 (+2.17)%

Market Cap

USD 2.01B

Volume

1.24M

Analyst Target

USD 114.83
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Haemonetics Corp is a health care company.It provides products to customers involved in the processing,handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes & reduce costs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.05 (-0.02%)

USD 66.85B
ALC Alcon AG

+0.60 (+0.69%)

USD 43.35B
RMD ResMed Inc

-11.77 (-4.76%)

USD 35.86B
BAX Baxter International Inc

-1.20 (-3.55%)

USD 17.26B
AVTR Avantor Inc

-0.21 (-0.96%)

USD 14.69B
ATR AptarGroup Inc

-0.20 (-0.11%)

USD 11.68B
TFX Teleflex Incorporated

-1.60 (-0.82%)

USD 9.08B
BLCO Bausch + Lomb Corp

+0.22 (+1.13%)

USD 6.88B
STVN Stevanato Group SpA

-0.19 (-0.92%)

USD 5.19B
WRBY Warby Parker Inc

-0.11 (-0.52%)

USD 2.03B

ETFs Containing HAE

XHE SPDR® S&P Health Care Eq.. 1.96 % 0.35 %

-1.55 (-1.68%)

USD 0.22B
RWM ProShares Short Russell20.. 0.00 % 0.95 %

+0.17 (+-1.68%)

USD 0.14B
SRTY ProShares UltraPro Short .. 0.00 % 0.95 %

+0.44 (+-1.68%)

USD 0.07B
TWM ProShares UltraShort Russ.. 0.00 % 0.95 %

+0.77 (+-1.68%)

USD 0.05B
TZA Direxion Daily Small Cap .. 0.00 % 0.95 %

+0.31 (+-1.68%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.20% 58% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.20% 58% F 46% F
Trailing 12 Months  
Capital Gain 4.46% 53% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.46% 53% F 21% F
Trailing 5 Years  
Capital Gain -22.09% 38% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.09% 38% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -0.87% 32% F 28% F
Dividend Return -0.87% 26% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.97% 58% F 32% F
Risk Adjusted Return -2.65% 26% F 21% F
Market Capitalization 2.01B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.